Prostacyclin analog beraprost sodium efficacy in primary glomerular disease or nephrosclerosis: Analysis of the Japanese subgroup in CASSIOPEIR study-Reference-Cited by-同舟云学术

Prostacyclin analog beraprost sodium efficacy in primary glomerular disease or nephrosclerosis: Analysis of the Japanese subgroup in CASSIOPEIR study

Published:2021-02-21 Issue:5 Volume:25 Page:551-564
ISSN:1744-9979
Container-title:Therapeutic Apheresis and Dialysis
language:en
Short-container-title:Ther Apher Dial

Author:

Kurumatani Hajimu¹^ORCID,Okada Kiyonobu¹,Origasa Hideki²,Fujita Toshiro³,Isono Masanao¹,Nakamoto Hidetomo⁴

Affiliation:

1. Toray Industries, Inc. Tokyo Japan

2. The University of Toyama Toyama Japan

3. The University of Tokyo Tokyo Japan

4. Saitama Medical University Saitama Japan

Funder

Astellas Pharma US

Toray Industries

Astellas Pharma

Publisher

Wiley

Subject

Nephrology,Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/1744-9987.13616

Reference30 articles.

1. Stereoselective synthesis of 5,6,7‐trinor‐4,8‐inter‐m‐phenylene‐PGI2 derivatives and their inhibitory activities to human platelet aggregation;Ohno K;Adv Prostaglandin Thromboxane Leukot Res,1985

2. Orally active prostacyclin analogue for cardiovascular disease;Nagaya N;Int Angiol,2010

3. Therapeutic effects of prostacyclin analog on crescentic glomerulonephritis of rat

4. Amelioration by beraprost sodium, a prostacyclin analogue, of established renal dysfunction in rat glomerulonephritis model

5. Improvement of dyslipidemia in OLETF rats by the prostaglandin I2 analog beraprost sodium

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prostacyclin Mitigates Renal Fibrosis by Activating Fibroblast Prostaglandin I2 Receptor;Journal of the American Society of Nephrology;2023-12-08

2. Correction to “Prostacyclin analog beraprost sodium efficacy in primary glomerular disease or nephrosclerosis: Analysis of the Japanese subgroup in CASSIOPEIR study”;Therapeutic Apheresis and Dialysis;2023-04-11

3. Change in albuminuria as a surrogate endpoint for cardiovascular and renal outcomes in patients with diabetes;Diabetes, Obesity and Metabolism;2023-03-08